1,916 material Form 8-K filings that 1,609 companies we cover made with the SEC in July 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
FB Financial Corporation reported second quarter 2026 net income of $58.6 million, or $1.13 per diluted share, compared with $1.10 in the prior quarter and $0.06 a year earlier, when results included a $60.5 million securities loss. Total revenue rose to $174.8 million and loans held for investment grew to $12.87 billion, while nonperforming loans rose to 1.17% of total loans. The company also repurchased 1,546,707 shares, or 3.01% of shares outstanding, during the quarter.
Net income of $58.6 million, or $1.13 per diluted share, versus $1.10 in Q1 2026 and $0.06 in Q2 2025
Adjusted diluted EPS of $1.14; adjusted pre-tax pre-provision net revenue of $83.6 million
Loans held for investment of $12.87 billion, an 11.6% annualized increase from the prior quarter
Nonperforming loans rose to 1.17% of total loans from 0.96% in the prior quarter, concentrated in three lending relationships
Edgewise Therapeutics completed the sale of its sevasemten muscular dystrophy program to Servier on July 10, 2026, receiving $1.55 billion in upfront cash plus up to $1.1 billion in additional milestone payments. The company says the proceeds strengthen its balance sheet and will fully fund development of its cardiovascular pipeline, led by EDG-7500, through potential approval.
Upfront cash consideration of $1.55 billion; milestone payments of up to $1.1 billion, for aggregate potential consideration of up to $2.65 billion.
Transaction completed July 10, 2026; Edgewise announced completion in a press release dated July 13, 2026.
Edgewise expects to start a Phase 3 trial of EDG-7500 in the fourth quarter of 2026 and a Phase 2 trial of EDG-15400 in HFpEF.
Edgewise intends to file pro forma financial information in a Form 8-K/A no later than four business days after completion.
On July 12, 2026, First Hawaiian agreed to acquire TriCo Bancshares in an all-stock transaction, with TriCo shareholders receiving 2.095 First Hawaiian shares per TriCo share, valued at $63.12 per share at the July 10 closing price. The companies expect the deal to close by the end of 2026, subject to regulatory and shareholder approvals. First Hawaiian also disclosed preliminary second-quarter net income of $73.4 million and diluted EPS of $0.60, up from $67.8 million and $0.55 in the prior quarter, though these figures may change after the closing procedures and audit review.
Merger Agreement signed July 12, 2026; TriCo shareholders to receive 2.095 First Hawaiian shares per TriCo share, valued at $63.12 per share as of July 10, 2026.
Upon closing, First Hawaiian and TriCo shareholders are expected to own about 65% and 35% of the combined company; the combined company will have about $34 billion in assets.
Preliminary Q2 2026 net income of $73.4 million and diluted EPS of $0.60, compared with $67.8 million and $0.55 in the prior quarter.
Closing expected by end of 2026; final second-quarter results to be released July 24, 2026.
Aebi Schmidt Holding AG furnished a press release and investor presentation dated July 13, 2026, marking one year since its acquisition of The Shyft Group and its NASDAQ listing. The company set a long-term target of more than $3 billion in annual revenue and a mid-teens adjusted EBITDA margin by 2030, and its investor presentation includes 2026 guidance. For shareholders, the filing reports higher first-quarter 2026 net sales and adjusted EBITDA than a year earlier, but it is a strategy update rather than a new full quarterly results release.
Long-term target of more than $3 billion in annual revenue and a mid-teens adjusted EBITDA margin by 2030
2026 guidance in the investor presentation: sales of $1.95 billion to $2.15 billion and adjusted EBITDA of $175 million to $195 million
Annual run-rate synergy target raised from $25 million to at least $40 million; full realization anticipated by mid-2027
Q1 2026 net sales of $455.5 million and adjusted EBITDA of $33.1 million, versus $453.8 million and $31.2 million in Q1 2025
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.